Moderna's stock jumps 5% premarket after narrower-than-expected loss and revenue beatMarket Watch • 08/03/23
Pfizer, Moderna Try To Squeeze Blood From A Stone. Why It Probably Won't Work.Investors Business Daily • 08/03/23
Moderna Reports Second Quarter 2023 Financial Results and Provides Business UpdatesAccesswire • 08/03/23
New Covid vaccines are coming to the U.S. this fall, but uptake may be low — Here's whyCNBC • 07/29/23
BioNTech And Moderna: Fallen Angels Of The COVID Era Are Buys Ahead Of EarningsSeeking Alpha • 07/27/23
Merck and Moderna launch late-stage trial of V940 with Keytruda as treatment for high-risk melanomaMarket Watch • 07/26/23
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) MelanomaBusiness Wire • 07/26/23
Moderna to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023Accesswire • 07/13/23